David J. Blythin
Merck & Co., Inc., Rahway, NJ, USA (United States)(US)
Publications by Year
Research Areas
Chemical Synthesis and Analysis, Receptor Mechanisms and Signaling, Phenothiazines and Benzothiazines Synthesis and Activities, Radical Photochemical Reactions, Neuroscience and Neuropharmacology Research
Most-Cited Works
- → The pharmacology of SCH 50911: a novel, orally-active GABA-beta receptor antagonist.(1995)77 cited
- → Cyclic urea derivatives as potent NK1 selective antagonists(2005)47 cited
- → Antiinflammatory activity of substituted 6-hydroxypyrimido[2,1-f]purine-2,4,8(1H,3H,9H)-triones. Atypical nonsteroidal antiinflammatory agents(1986)43 cited
- → Discovery of a highly potent series of oxazole-based phosphodiesterase 4 inhibitors(2007)33 cited
- → Cyclic urea derivatives as potent NK1 selective antagonists. Part II: Effects of fluoro and benzylic methyl substitutions(2005)30 cited
- → Enantioselective syntheses of carbocyclic ribavirin and its analogs: linear versus convergent approaches(2000)30 cited
- → Biological evaluation and interconversion studies of rotamers of SCH 351125, an orally bioavailable CCR5 antagonist(2003)29 cited
- → Substituted morpholine-2S-acetic acid derivatives: Sch 50911 and related compounds as novel GABAB antagonists(1996)26 cited
- → Discovery of oxazole-based PDE4 inhibitors with picomolar potency(2012)23 cited
- → Synthesis and resolution of β-(aminomethyl)-4-chlorobenzeneethanesulfinic acid a potent gabaB receptor ligand(1995)18 cited